Fluid administration in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: neither too much nor too little
Maria Elvira Castellanos Garijo; Ana Sepúlveda Blanco; Jose Tinoco Gonzalez; Alicia Merinero Casado; Juan Ignacio Medina de Moya; Gabriel Yanes Vidal; Ana Forastero Rodriguez; Cristobalina Ángeles Martin García; Francisco Cristobal Muñoz-Casares; Javier Padillo Ruiz
Intraoperative fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy plays an important role in postoperative morbidity. Studies have found an association between overload fluid therapy and increased postoperative complications, advising restrictive intraoperative fluid therapy. Our objective in this study was to compare the morbidity associated with restrictive versus non-restrictive intraoperative fluid therapy.
Retrospective analysis of a database collected prospectively in the Anesthesiology Service of Virgen del Rocío Hospital, from December 2016 to April 2019. One hundred and six patients who underwent complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy were divided into two cohorts according to Fluid Therapy received 1. Restrictive ≤ 9 mL.kg-1.h-1 (34 patients), 2. Non-restrictive ≥ 9 mL.kg-1.h-1 (72 patients). Percentage of major complications (Clavien-Dindo grade III–IV) and length hospital stay were the main outcomes variables.
Of the 106 enrolled patients, 68.9% were women; 46.2% had ovarian cancer, 35.84% colorectal cancer, and 7.5% peritoneal cancer. The average fluid administration rate was 11 ± 3.58 mL.kg-1.h-1. The restrictive group suffered a significantly higher percentage of Clavien-Dindo grade III–IV complications (35.29%) compared with the non-restrictive group (15.27%) (p = 0.02). The relative risk associated with restrictive therapy was 1.968 (95% confidence interval: 1.158–3.346). We also found a significant difference for hospital length of stay, 20.91 days in the restrictive group vs 16.19 days in the non-restrictive group (p = 0.038).
Intraoperative fluid therapy restriction below 9 mL.kg-1.h-1 in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy was associated with a higher percentage of major postoperative complications.
1 N.J. Gusani, S.W. Cho, C. Colovos, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center Ann Surg Oncol, 15 (2008), pp. 754-763
2 D. Baratti, S. Kusamura, B. Laterza, et al. Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy World J Gastrointest Oncol, 2 (2010), pp. 36-43
3 C. Raspé, L. Flöther, R. Schneider, et al. Best practice for perioperative management of patients with cytoreductive surgery and HIPEC Eur J Surg Oncol, 43 (2017), pp. 1013-1027
4 S. Malfroy, F. Wallet, D. Maucort-Boulch, et al. Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: Risk factors for ICU admission and morbidity prognostic score Surg Oncol, 25 (2016), pp. 6-15
5 J. Esquivel, F. Angulo, R.K. Bland, et al. Hemodynamic and Cardiac Function Parameters During Heated Intraoperative Intraperitoneal Chemotherapy Using the Open “Coliseum Technique” Ann Surg Oncol, 7 (2000), pp. 296-300
6 K. Holte, N.B. Foss, J.L. Andersen, et al. Liberal or restrictive fluid administration in fast-track colonic surgery: a randomized double-blind study Br J Anaesth, 99 (2007), pp. 500-508
7 GP Joshi Intraoperative fluid restriction improves outcome after major elective gastrointestinal surgery Anesth Analg, 101 (2005), pp. 601-605
8 B. Brandstrup, H. Tønnesen, R. Beier-Holgersen, et al. Danish Study Groupon Perioperative Fluid Therapy. Effects of intravenous fluid restriction non postoperative complications: comparison of two Perioperative fluid regimens: a randomized assessor-blinded multicentertrial Ann Surg, 238 (2003), pp. 641-648
9 V. Nisanevich, I. Felsenstein, G. Almogy, et al. Effect of intraoperative fluid management on outcome after intraabdominal surgery Anesthesiology, 103 (2005), pp. 25-32
10 O.S. Eng, S. Dumitra, M. O’Leary, et al. Association of Fluid Administration With Morbidity in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy JAMA Surg, 152 (2017), pp. 1156-1160
11 M.T. Giglio, M. Marucci, M. Testini, et al. Goal-directed haemodynamic therapy and gastrointestinal complications in major surgery: a meta-analysis of randomized controlled trials Br J Anaesth, 103 (2009), pp. 637-646
12 L. Colantonio, C. Claroni, L. Fabrizi, et al. A randomized trial of goal directed vs. standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy J Gastrointest Surg, 19 (2015), pp. 722-729
13 T.J. Gan, A. Soppitt, M. Maroof, et al. Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery Anesthesiology, 97 (2002), pp. 820-826
14 N. Brienza, M.T. Giglio, M. Marucci, et al. Does perioperative hemodynamic optimization protect renal function in surgical patients? A meta-analytic study Crit Care Med, 7 (2009), pp. 2079-2090
15 N. MacDonald, T. Ahmad, O. Mohr, et al. Dynamic preload markers to predict ﬂuid responsiveness during and after major gastrointestinal surgery: an observational substudy of the OPTIMISE trial Br J Anaesthesia, 114 (2015), pp. 598-604
16 K. Bouattour, J.L. Teboul, L. Varin, et al. Preload Dependence Is Associated with Reduced Sublingual Microcirculation during Major Abdominal Surgery Anesthesiology, 130 (2019), pp. 541-549
17 D. Dindo, N. Demartines, P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg, 240 (2004), pp. 205-213
18 W. Raue, N. Tsilimparis, A. Bloch, et al. Volume Therapy and Cardiocircular Function during Hyperthermic Intraperitoneal Chemotherapy Eur Surg Res, 43 (2009), pp. 365-372
19 C.N. Schluermann, J. Hoeppner, C. Benk, et al. Intra-abdominal pressure, Cardiac Index and vascular resistance during hyperthermic intraperitoneal chemotherapy: a prospective observational study Minerva Anestesiol, 82 (2016), pp. 160-169
20 F. Díaz, B. Erranz, A. Donoso, et al. Influence of tidal volume on pulse pressure variation and stroke volume variation during experimental intra-abdominal hypertension BMC Anesthesiol, 15 (2015), p. 127
21 C.L. Verdant, D. De Backer, A. Bruhn, et al. Evaluation of sublingual and gut mucosal microcirculation in sepsis: a quantitative analysis Crit Care Med, 37 (2009), pp. 2875-2881
22 M. Jacquet-Lagrèze, B. Allaouchiche, D. Restagno, et al. Gut and sublingual microvascular effect of esmolol during septic shock in a porcine model Crit Care, 19 (2015), p. 241
23 AF de Bruin, VN Kornmann, K van der Sloot, et al. Sidestream dark field imaging of the serosal microcirculation during gastrointestinal surgery Colorectal Dis, 18 (2016), pp. 103-110
24 J. Ripollés, Á Espinosa, R. Casans, et al. Colloids versus crystalloids in objective-guided fluid therapy, systematic review and meta-analysis. Too early or too late to draw conclusions Braz J Anesthesiol, 65 (2015), pp. 281-291
25 K. Berend, A.P. de Vries, R.O. Gans Physiological Approach to Assessment of Acid–Base Disturbances N Engl J Med, 371 (2014), pp. 14334-14345
26 British Consensus Guidelines on Intravenous Fluid Therapy for Adult Surgical Patients. GIFTASUP. Powell-Tuck J, Gosling P, Lobo DN, et al. (Updated March 2011).
27 S.A. McCluskey, K. Karkouti, D. Wijeysundera, et al. Hyperchloremia after noncardiac surgery is independently associated with increased morbidity and mortality: a propensity-matched cohort study Anesth Analg, 117 (2013), pp. 412-421
28 A.D. Shaw, S.M. Bagshaw, S.L. Goldstein, et al. Major complications, mortality, and resource utilization after open abdominal surgery: 0.9% saline compared to Plasma-Lyte Ann Surg, 255 (2012), pp. 821-829
29 D. Kusamura, R. Baratti, B. Younan, et al. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity Ann Surg Oncol, 14 (2007), pp. 2550-2558
30 S.A. Naﬀouje, K.A. Tulla, R. Chorley, et al. Acute kidney injury increases the rate of major morbidities in cytoreductive surgery and HIPEC Ann Med Surg, 35 (2018), pp. 163-168